Currently, clinically validated biomarkers that predict response to ICT include high microsatellite instability (MSI-H, occurs in only ~4% of human cancer)12,13, tumor-cell PD-L1 expression14, and tumor mutational burden (TMB)15–17. This evidence concerns the gene CD274 and cancer.